Related Experiment Video

Updated: Feb 18, 2026

Isolation of Neonatal Extrahepatic Cholangiocytes
07:54

Isolation of Neonatal Extrahepatic Cholangiocytes

Published on: June 5, 2014

10.9K

Hepatic paragonimiasis in a 15-month-old girl: a case report

Zongrong Gong1,2, Zhicheng Xu3, Chuanfen Lei4

  • 1Department of Pediatrics, West China Second University Hospital, Sichuan University, No. 20,3rd Section of Renmin South Road, Chengdu, 610041, China.

BMC Pediatrics
|November 17, 2017
PubMed

Insights

Hepatic paragonimiasis (HP), a rare parasitic infection in infants, was diagnosed in a 15-month-old girl presenting with fever and liver lesions. Prompt treatment with praziquantel led to rapid improvement, highlighting the importance of considering HP in endemic areas.

Area of Science:

  • Parasitology
  • Pediatric Infectious Diseases
  • Hepatology

Background:

  • Hepatic paragonimiasis (HP) is a rare zoonotic parasitic disease, with limited reports and no documented cases in infants.
  • This study addresses the first reported case of HP in an infant.

Observation:

  • A 15-month-old infant presented with a month-long mild fever, hepatomegaly, and characteristic low-density liver lesions on imaging.
  • Diagnostic confirmation involved pathological examination revealing Charcot-Leyden crystals and serological detection of antibodies against Paragonimus westermani.

Findings:

  • The infant was diagnosed with hepatic paragonimiasis based on clinical, pathological, and serological evidence.
  • Treatment with praziquantel (75 mg/kg/day for 3 days) resulted in swift resolution of all clinical symptoms.

Implications:

  • Clinicians should consider paragonimiasis in infants presenting with fever, hepatomegaly, and liver lesions, especially in endemic regions.
  • Early diagnosis and treatment of HP in infants are crucial for favorable outcomes.
Abstract

Keywords:
Diagnosis; infantHepatic paragonimiasisParagonimiasis

More Related Videos

Cutaneous Leishmaniasis in the Dorsal Skin of Hamsters: a Useful Model for the Screening of Antileishmanial Drugs11:36

Cutaneous Leishmaniasis in the Dorsal Skin of Hamsters: a Useful Model for the Screening of Antileishmanial Drugs

Published on: April 21, 2012

22.6K
A Silver Nanoparticle Method for Ameliorating Biliary Atresia Syndrome in Mice07:48

A Silver Nanoparticle Method for Ameliorating Biliary Atresia Syndrome in Mice

Published on: October 13, 2018

8.1K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
258
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
212
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
932
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
289
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
334
Hepatic Portal System01:21

Hepatic Portal System

The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
6.5K